EUVIMEDEUVIMED entdecken
Crossref

Efficacy and Safety of the Oral Gonadotropin‐Releasing Hormone Antagonist DW4902 for Heavy Menstrual Bleeding in Uterine Fibroids: A Randomized, Double‐Blind, Placebo‐Controlled Phase II Trial

Jae‐yeon Song, Jung Yoon Park, Young Sik Choi, Dong‐Yun Lee, Sung Eun Kim, Jung Ryeol Lee, Kyong Wook Yi, SiHyun Cho, Cho Chi‐Heum, Miran Kim, Jong Kil Joo, Jung‐Ho Shin und 1 weitere

BJOG: An International Journal of Obstetrics & Gynaecology · 18.11.2026

DOI: 10.1111/1471-0528.70385 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BJOG: An International Journal of Obstetrics & Gynaecology, online erschienen am 18.11.2026. Verfasst von Jae‐yeon Song und 12 weiteren Autor:innen. Die Arbeit nennt 52 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate the efficacy and safety of DW4902, a novel oral gonadotropin‐releasing hormone (GnRH) antagonist, in premenopausal women with uterine fibroids and heavy menstrual bleeding (HMB).

Design

Multicenter, randomized, double‐blind, placebo‐controlled Phase II trial.

Setting

Twelve tertiary hospitals in Korea. Population Premenopausal women with uterine fibroids and heavy menstrual bleeding, defined as a screening pictorial blood assessment chart score (PBAC) ≥ 120.

Methods

Seventy‐one women with uterine fibroids, HMB (screening PBAC ≥ 120) and other predefined criteria were randomized to placebo or DW4902 160, 240 or 320 mg once daily. Main Outcome Measures The primary endpoint was the proportion achieving PBAC < 10 during Weeks 6–12. Secondary endpoints included amenorrhea, haemoglobin change, fibroid and uterine volumes, pain scores, bone mineral density and safety.

Results

During Weeks 6–12, PBAC < 10 was achieved by 73.33%–100.00% of participants receiving DW4902 160, 240 and 320 mg ( p < 0.0001). Amenorrhea rates were likewise significantly higher in the DW4902 groups (≥ 73.33%), with bleeding suppression evident from Weeks 2 to 6. Haemoglobin levels increased significantly in the 160 and 240 mg groups. Fibroid and uterine volumes and fibroid‐related pain were significantly reduced across all DW4902 dose groups. Hormone levels recovered after treatment discontinuation, and lumbar spine bone mineral density showed modest, reversible changes. Adverse events were mostly mild and comparable between groups, with no serious drug‐related events.

Conclusions

DW4902 demonstrated a robust efficacy in reducing menstrual bleeding and improving fibroid‐related outcomes with an acceptable short‐term safety and bone density profile.

Zitieren

APA

Song, J., Park, J. Y., Choi, Y. S., Lee, D., Kim, S. E., Lee, J. R., Yi, K. W., Cho, S., Chi‐Heum, C., Kim, M., Joo, J. K., Shin, J., & Kim, S. H. (2026). Efficacy and Safety of the Oral Gonadotropin‐Releasing Hormone Antagonist DW4902 for Heavy Menstrual Bleeding in Uterine Fibroids: A Randomized, Double‐Blind, Placebo‐Controlled Phase II Trial. BJOG: An International Journal of Obstetrics & Gynaecology. https://doi.org/10.1111/1471-0528.70385

Vancouver

Song J, Park JY, Choi YS, Lee D, Kim SE, Lee JR, et al. Efficacy and Safety of the Oral Gonadotropin‐Releasing Hormone Antagonist DW4902 for Heavy Menstrual Bleeding in Uterine Fibroids: A Randomized, Double‐Blind, Placebo‐Controlled Phase II Trial. BJOG: An International Journal of Obstetrics & Gynaecology. 2026. doi:10.1111/1471-0528.70385

BibTeX
@article{Song2026,
  author = {Song, Jae‐yeon and Park, Jung Yoon and Choi, Young Sik and Lee, Dong‐Yun and Kim, Sung Eun and Lee, Jung Ryeol and Yi, Kyong Wook and Cho, SiHyun and Chi‐Heum, Cho and Kim, Miran and Joo, Jong Kil and Shin, Jung‐Ho and Kim, Sung Hoon},
  title = {Efficacy and Safety of the Oral Gonadotropin‐Releasing Hormone Antagonist DW4902 for Heavy Menstrual Bleeding in Uterine Fibroids: A Randomized, Double‐Blind, Placebo‐Controlled Phase II Trial},
  journal = {BJOG: An International Journal of Obstetrics & Gynaecology},
  year = {2026},
  doi = {10.1111/1471-0528.70385}
}
Kostenlos starten →